版权说明 操作指南
首页 > 成果 > 详情

Synthesis of Myrtucommulone D: A Selective Inhibitor of Tyrosyl-DNA Phosphodiesterase 2 Promoting Drug Resistance Reversal in Lung Cancer Cells

认领
导出
Link by DOI
反馈
分享
QQ微信 微博
成果类型:
期刊论文
作者:
Zhang, Yu;Xiao, Long-Gao;Peng, Xing;Yang, Hao;Wang, Zhen
通讯作者:
Wang, Z
作者机构:
[Zhang, Yu; Wang, Zhen] Univ South China, Sch Pharmaceut Sci, Hengyang Med Sch, Hengyang 421001, Peoples R China.
[Xiao, Long-Gao] Chinese Acad Sci, State Key Lab Phytochem & Plant Resources West Chi, Kunming Inst Bot, Kunming 650204, Peoples R China.
[Peng, Xing] Sun Yat sen Univ, Sch Pharmaceut Sci, Guangzhou 510006, Peoples R China.
[Yang, Hao] Ningxia Med Univ, Sch Pharm, Yinchuan 750004, Peoples R China.
通讯机构:
[Wang, Z ] U
Univ South China, Sch Pharmaceut Sci, Hengyang Med Sch, Hengyang 421001, Peoples R China.
语种:
英文
关键词:
Anti-tumor agent;Drug resistance;Phloroglucinol derivatives;Tyrosyl-DNA phosphodiesterase 2 Inhibitor
期刊:
Revista Brasileira de Farmacognosia
ISSN:
0102-695X
年:
2024
机构署名:
本校为第一且通讯机构
摘要:
Chemoresistance has emerged as a critical barrier in the treatment of lung cancer. The recently discovered DNA repair enzyme, tyrosyl-DNA phosphodiesterase 2, can repair topoisomerase 2-mediated DNA damage, thereby contributing to cancer cell resistance. This study reported the identification of the natural product myrtucommulone D as a selective tyrosyl-DNA phosphodiesterase 2 inhibitor and presented its first enantioselective total synthesis. The enantiomeric excess (ee) of (+)- and (-)-myrtucommulone D was determined to be 95.3 and 95.1%, respectively. Biological experiments indicated that ...

反馈

验证码:
看不清楚,换一个
确定
取消

成果认领

标题:
用户 作者 通讯作者
请选择
请选择
确定
取消

提示

该栏目需要登录且有访问权限才可以访问

如果您有访问权限,请直接 登录访问

如果您没有访问权限,请联系管理员申请开通

管理员联系邮箱:yun@hnwdkj.com